AstraZeneca PLC
AZN
$171.34
-$1.96-1.13%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.41% | 12.51% | 4.11% | 11.99% | 11.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.41% | 12.51% | 4.11% | 11.99% | 11.74% |
| Cost of Revenue | 2.35% | 19.28% | 47.03% | -9.38% | 13.28% |
| Gross Profit | 7.25% | 11.17% | -3.16% | 18.27% | 11.43% |
| SG&A Expenses | 14.32% | 8.64% | 18.86% | -1.74% | -1.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -92.41% | -229.79% | 239.47% | -256.00% | -31.67% |
| Total Operating Expenses | 7.54% | 10.38% | 22.43% | 0.61% | 7.43% |
| Operating Income | 2.88% | 18.40% | -32.55% | 73.88% | 27.75% |
| Income Before Tax | -10.49% | 15.05% | 57.80% | 77.46% | 30.45% |
| Income Tax Expenses | -57.14% | 73.18% | 80.72% | 79.49% | 44.78% |
| Earnings from Continuing Operations | 2.45% | 5.48% | 55.27% | 76.90% | 26.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -150.00% | 80.00% | -- | 50.00% | 300.00% |
| Net Income | 2.33% | 5.62% | 55.07% | 77.26% | 27.14% |
| EBIT | 2.88% | 18.40% | -32.55% | 73.88% | 27.75% |
| EBITDA | 6.04% | 15.25% | -21.64% | 32.83% | 21.66% |
| EPS Basic | 2.26% | 5.69% | 54.98% | 77.15% | 27.06% |
| Normalized Basic EPS | 3.52% | 18.42% | -34.46% | 82.14% | 30.59% |
| EPS Diluted | 2.55% | 5.35% | 53.94% | 78.02% | 27.64% |
| Normalized Diluted EPS | 3.51% | 18.34% | -34.46% | 82.36% | 30.76% |
| Average Basic Shares Outstanding | 0.06% | -0.06% | 0.06% | 0.06% | 0.06% |
| Average Diluted Shares Outstanding | 0.06% | 0.00% | 0.06% | -0.06% | -0.06% |
| Dividend Per Share | -98.97% | -- | 3.33% | -- | 3.00% |
| Payout Ratio | -0.90% | -0.07% | -- | -0.42% | -0.54% |